Abrégé

A cancer treatment apparatus for applying a magnetic field to a living body is disclosed. The cancer treatment apparatus includes a magnetic field generator configured to generate a magnetic field; a power supply unit configured to supply a drive current to the magnetic field generator; and a controller configured to control the drive current supplied from the power supply unit, based on information on a cross section of a portion of a living body to which the magnetic field generated by the magnetic field generator is applied.

Classes IPC  ?

• A61N 2/00 - Magnétothérapie
• A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants

Abrégé

Disclosed are a means which enables simple and rapid detection of the presence or absence, and of the degree, of HR activity in an individual, and a means which is useful for detection and treatment of homologous recombination-restored cancer for which no treatment means is available at present. The nucleic acid construct of the present invention is a nucleic acid construct comprising a set of a first nucleic acid molecule and a second nucleic acid molecule, the first nucleic acid molecule comprising: a promoter region; and a mutant gene sequence operably linked downstream thereof, the mutant gene sequence being constituted by a gene sequence encoding a protein and a cleavage site arranged inside thereof; the second nucleic acid molecule comprising a complementation region capable of replacing, by homologous recombination, a partial region comprising the cleavage site in the mutant gene sequence, the complementation region being constituted by a first homologous region and a second homologous region. The construct is useful as a measurement reagent or kit for homologous recombination activity, a diagnostic agent for homologous recombination-deficient cancer, a therapeutic agent for homologous recombination-restored cancer, or the like.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

[Problem] To provide a simpler testing method for a NAFLD or an assisting method for the diagnosis of a NAFLD, which is excellent in sensitivity and specificity. [Solution] Provided is a testing method for a nonalcoholic fatty liver disease (NAFLD), the method including a step for detecting or quantifying L-methionine in a biological sample derived from a subject.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

[Problem] To provide a simpler testing method for a NAFLD or an assisting method for the diagnosis of a NAFLD, which is excellent in sensitivity and specificity. [Solution] Provided is a testing method for a nonalcoholic fatty liver disease (NAFLD), the method including a step for detecting or quantifying D-histidine in a biological sample derived from a subject.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present disclosure relates to construction of three-dimensional organs from pluripotent stem cells. The present disclosure also relates to a method of forming a cell condensate for self-organization.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
• C12N 5/074 - Cellules souches adultes

Abrégé

Provided is a forceps device (1) configured to easily change a state of a ratchet mechanism (19). The forceps device (1) includes an opening/closing drive unit (6) that opens an opening/closing portion (4) when positioned at an open position (O) and closes the opening/closing portion (4) when positioned at a closed position (C), and a ratchet mechanism (19) transitions between a restriction state in which the opening/closing drive unit (6) is restricted to move in the open position (O) direction and a restriction release state in which the move is not restricted. The ratchet mechanism (19) includes an operation portion (27) that projects rearward from a main body (3) of the forceps device (1) and is operated to cause the transition of the state of the ratchet mechanism (19).

Classes IPC  ?

• A61B 17/29 - Pinces pour la chirurgie faiblement invasive
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux

Abrégé

An alternating magnetic field having a frequency, at which a sufficient antitumor effect can be obtained, is enabled to be applied to a living body for a previously prescribed period of time while restricting an amount of heat generation from the living body. A cancer treatment apparatus includes a magnetic field generator configured to generate an alternating magnetic field to be applied to a living body, and a magnetic field controller configured to increase an intensity of the alternating magnetic field generated by the magnetic field generator stepwise until a first period of time elapses since application of the alternating magnetic field to the living body, and to set the intensity of the alternating magnetic field to a previously set maximum value from elapse of the first period of time until a timing to end the application of the alternating magnetic field.

Classes IPC  ?

• A61N 2/00 - Magnétothérapie
• A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants

Abrégé

An alternating magnetic field having a frequency, at which a sufficient antitumor effect can be obtained, is enabled to be applied to a living body while restricting an amount of heat generation. A cancer treatment apparatus includes a magnetic field generator including a coil configured to generate an alternating magnetic field to be applied to a living body, and a cooler configured to cool a magnetic field application part of the living body in which a temperature rises in response to application of the alternating magnetic field.

Classes IPC  ?

• A61N 2/00 - Magnétothérapie
• A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants

Abrégé

The present disclosure relates to an organ bud and a method of preparing an organ bud.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A01K 67/0271 - Vertébrés chimériques, p. ex. comprenant des cellules exogènes
• A61L 27/38 - Cellules animales

Abrégé

This heart failure estimation device acquires an image or video obtained by imaging the face of a patient. The heart failure estimation device extracts one or more feature parameters from the image or video. On the basis of the one or more feature parameters, the heart failure estimation device estimates the degree of heart failure of the patient.

Classes IPC  ?

• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
• A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
• A61B 5/107 - Mesure de dimensions corporelles, p. ex. la taille du corps entier ou de parties de celui-ci
• G06T 7/00 - Analyse d'image
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

The present invention provides a means for reconstituting tissues and organs having mature functions.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The nucleic acid construct according to the present invention has such a structure that a protein can be expressed by the occurrence of at least two times of a recombinant reaction by single-strand annealing (SSA), is useful for the diagnosis and treatment of mismatch repair (MMR) deficient cancer, is applicable to the searching of a factor capable of regulating a reaction of MMR or SSA, an inhibitor or an activator for the reaction of MMR or SSA, and is also applicable to the prediction of whether of not a gene mutation identified in a cancer patient is a mutation that deteriorates an MMR activity. A conventional SSA construct that has been developed in the past by the present inventors has such a structure that a protein is expressed by the occurrence of one time of a SSA reaction. According to the construct of the present invention, the difference in the protein expression amount (activity) between the case where an MMR deficient is present and the case where an MMR deficient is absent occurs more greatly compared with that in the conventional SSA construct. Therefore, the construct of the present invention is expected to act on an MMR deficient cell more specifically and provide, for example, a treatment means having fewer adverse side effects.

Classes IPC  ?

• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

This culture device comprises a container body that houses a culture liquid, and a culture chip that forms a culture chamber inside the container body, wherein: the container body has a light-permeable and gas-permeable bottom wall; and the culture chip has a frame that is in contact with the top surface of the bottom wall, and a membrane member that is permeable to a liquid or a liquid-containing material and is fixed to the top surface of the frame to form the culture chamber together with the bottom wall and the frame.

Classes IPC  ?

• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12N 5/076 - Cellules du spermeSpermatogonies

Abrégé

A production method for an artificial organ according to the present invention involves performing a decellularization treatment on a mammalian organ or a portion thereof to obtain a decellularized organ or a portion thereof and performing a cellularization treatment that grafts cells onto the decellularized organ or portion thereof to obtain an organ onto which the cells have been grafted. The cellularization treatment involves injecting an organoid that includes cells of the relevant organ or cells that can differentiate into cells of the relevant organ into the decellularized organ or portion thereof and infusing the blood vessels of the decellularized organ or portion thereof with cells of the relevant organ or cells that can differentiate into cells of the relevale organ. An artificial organ according to the present invention is obtained by means of the production method for an artificial organ.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The present invention provides drug toxicity evaluation platforms (such as an evaluation method and a kit therefor) that enable detailed analysis of the possibility and the like of developing drug-induced damage (such as DILI) to the liver and other organs. The method for evaluating drug toxicity of the present invention includes: a step of adding a drug to a co-culture system of an organoid and blood cells; and a step of evaluating the toxicity of the drug to the organoid.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/078 - Cellules du sang ou du système immunitaire

Abrégé

The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc.　A compound represented by formula (1) or a pharmaceutically acceptable salt thereof. (Here, in formula (1), R1, R2, R3, R4, X, Y, and Z are each as defined in the specification.)

Classes IPC  ?

• C07D 471/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes du système condensé, au moins un cycle étant un cycle à six chaînons avec un atome d'azote, non prévus dans les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/5365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/5386 - 1,4-Oxazines, p. ex. morpholine condensées en spiro ou formant une partie de systèmes cycliques pontés
• A61K 31/5395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines ayant plusieurs atomes d'azote dans le même cycle, p. ex. oxadiazines
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07D 498/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
• C07D 513/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou

Abrégé

Provided is a culture chamber capable of preparing spheroids with a uniform size with high efficiency and having a micro-space structure which is designed to facilitate replacement of a medium and harvesting of cells. The culture chamber includes a plurality of recesses (10) each formed of a bottom portion (11) and an opening portion (12). The bottom portion (11) has one of a hemispherical shape and a truncated cone shape and the opening portion (12) is defined by a wall that surrounds an area from a boundary between the opening portion (12) and the bottom portion (11) to an end of each of the recesses (10), the wall having a taper angle in a range from 1 degree to 20 degrees. An equivalent diameter of the boundary is in a range from 50 μm to 2 mm and a depth from a bottom of the bottom portion (11) to the end of each of the recesses is in a range from 0.6 or more times to 3 or less times the equivalent diameter, and the wall defining the opening portion (12) forms a surface continuous to the bottom portion (11) and an inclination of the continuous surface changes at the boundary.

Classes IPC  ?

• C12M 1/24 - Appareillage pour l'enzymologie ou la microbiologie en forme de tube ou de bouteille
• C12M 1/32 - Inoculateur ou échantillonneur du type à champs multiples ou en continu

Abrégé

An object of the present invention is to provide a biomarker that enables selection of an embryo having a high rate of implantation and pregnancy, that is, an embryo having high fertility, from embryos obtained through embryo culture after in vitro fertilization in infertility treatment, and a criterion therefor. Provided is a criterion that enables identification of an ovum suitable for implantation and pregnancy based on measurement of the concentration of soluble CD163 which is present in follicular fluid collected at the same time as an ovum in ovum pick up in infertility treatment, or which is present in serum immediately before the ovum pick up.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention provides a method for mass producing cell aggregates such as artificial organoids through an approach that differs entirely from previous methods. Specifically, provided is a method for producing cell aggregates that includes a step in which a mixture of mesenchymal stem cells, vascular endothelial cells, and organ cells are filled into microfibers, and the mixture is suspension cultured to form cell aggregates.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61K 35/407 - FoieHépatocytes
• A61K 35/44 - VaisseauxCellules de muscles vasculaires lissesCellules endothélialesCellules progénitrices endothéliales
• A61K 35/545 - Cellules souches embryonnairesCellules souches pluripotentesCellules souches pluripotentes induitesCellules souches non caractérisées
• A61L 27/38 - Cellules animales
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux

Abrégé

This information processing device acquires speech data that is time series data of the speech spoken by a user. The information processing device computes state information that represents a cardiac condition of a user, and outputs the computed condition information on the basis of the speech data.

Classes IPC  ?

• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge

Abrégé

The present invention provides a marker gene capable of detecting the undifferentiated cells that remain or become included in a differentiated cell population. Undifferentiated cells present in a differentiated cell population are detected by using at least one gene selected from the group consisting of LINC00678 and PRDM14 as an undifferentiation marker. A method of detecting undifferentiated cells; a method of using the gene as an undifferentiation marker; and a kit for detecting undifferentiated cells. A method of selecting an undifferentiated cell clone is also provided.

Classes IPC  ?

• C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes

Abrégé

A power supply apparatus includes a power supply configured to apply an alternating current to a magnetic field generation apparatus; and a controller configured to control the alternating current applied by the power supply. The controller controls the power supply to apply the alternating current having a waveform pattern including a plurality of current waveforms having different frequency spectrums from each other.

Classes IPC  ?

• A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
• A61N 1/40 - Application de champs électriques par couplage inductif ou capacitif
• H05B 6/06 - Commande, p. ex. de la température, de la puissance
• H05B 6/04 - Sources de courant
• G03G 15/20 - Appareils pour procédés électrographiques utilisant un dessin de charge pour le fixage, p. ex. par la chaleur

Abrégé

[Object] To provide a cancer treatment device that monitors a magnetic field applied to an affected area or monitors a temperature of the affected area or around the affected area. [Means of Achieving the Object] A cancer treatment system includes a magnetic field generator configured to generate an alternating current magnetic field to be applied to a cancer affected area, a magnetic field measurer configured to measure a magnitude of the magnetic field generated by the magnetic field generator, wherein the cancer affected area is inserted into the magnetic field generated by the magnetic field generator to treat cancers.

Classes IPC  ?

• A61N 2/04 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants utilisant des champs variables, p. ex. des champs basse fréquence ou des champs pulsés

Abrégé

An object of the present invention is to provide a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method which make it possible to simply detect SARS-CoV-2 with higher sensitivity. According to the present invention, there is provided a SARS-CoV-2 detection kit which is for specifically detecting a nucleocapsid protein contained in a biological specimen and contains at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), the SARS-CoV-2 detection kit including a first container that houses a silver-containing compound, and a second container that houses a reducing agent capable of reducing silver ions, in which the antibody includes at least one antibody that belongs to a subclass IgG2b.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/553 - Support métallique ou recouvert d'un métal

Abrégé

The present invention addresses the problem of providing an evaluation method, etc., capable of providing reliable information that can be used as a reference for understanding an individual difference in the expression of the relative pharmacological action of a combination of an immune checkpoint inhibitor with an anticancer drug, which is a concomitant agent, compared to the pharmacological action of the immune checkpoint inhibitor alone. The present embodiment evaluates the relative pharmacological action of a combination of an immune checkpoint inhibitor with an anticancer drug, which is a concomitant agent, in a subject to be evaluated, compared to the pharmacological action of the immune checkpoint inhibitor alone, by using the concentration of at least one metabolite selected from among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA and XA in the blood of the subject to be evaluated.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention addresses the problem of providing a highly sensitive and highly specific means for detecting a protein constituting a nucleocapsid derived from SARS-CoV-2. The above problem has been solved by, for example, an antibody binding to a protein constituting the nucleocapsid derived from SARS-CoV-2 or a fragment thereof, or a combination thereof; a method for detecting, from a sample, a protein constituting the nucleocapsid derived from SARS-CoV-2 using said antibody or a fragment thereof, or a combination thereof; and a kit for detecting a protein constituting the nucleocapsid derived from SARS-CoV-2, the kit containing said antibody or a fragment thereof, or a combination thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• G01N 33/531 - Production de matériaux de tests immunochimiques
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible

Abrégé

The present invention provides a sensitive and simple detection method, and a kit therefor, which detects residual undifferentiated human pluripotent stem cells in an intermediate product and/or a final product of a regenerative medical products, using an isothermal nucleic acid amplification method, and specifically, a LAMP method. A method for detecting presence or absence of undifferentiated cells in a non-undifferentiated cell population, wherein RNA derived from an undifferentiation marker gene exhibiting a significant difference in expression level between the undifferentiated cells and the non-undifferentiated cells in a sample containing a nucleic acid derived from the cell population of interest is detected by the isothermal nucleic acid amplification method. The kit for detecting presence or absence of undifferentiated cells in a non-undifferentiated cell population comprises a reagent with which RNA derived from an undifferentiation marker gene exhibiting a significant difference in expression level between the undifferentiated cells and the non-undifferentiated cells is detected by the isothermal nucleic acid amplification method.

Classes IPC  ?

• C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]

Abrégé

The present invention addresses the problem of providing a means for detecting a constituting protein of nucleocapsid derived from SARS-CoV-2. This problem has been solved by providing an antibody binding to a constituting protein of nucleocapsid derived from SARS-CoV-2 or a fragment of the antibody, a method for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid with the use of the antibody or a fragment thereof, a kit for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid, said kit containing the antibody or a fragment thereof, etc.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

An object of the invention is to provide a method for detecting pancreatic cancer and a reagent that can be used for the method. The method is a method for detecting pancreatic cancer, characterized by comprising measuring the amount of TFPI2 in a body fluid collected from a subject. In addition, an antibody that specifically recognizes the TFPI2 processing polypeptide and intact TFPI2 is included in the reagent for detecting pancreatic cancer.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10−9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• C12N 9/99 - Inactivation des enzymes par traitement chimique
• C12N 15/09 - Technologie d'ADN recombinant
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression

Abrégé

Provided is a forceps device (1) that enables easy switching between states of a ratchet mechanism (19). The forceps device (1) comprises: an opening/closing drive part (6) that opens an opening/closing part (4) when positioned in an open position (O) and closes the opening/closing part (4) when positioned in a closed position (C); and a ratchet mechanism (19) that transitions between a restricted state in which movement of the opening/closing drive part (6) toward the open position (O) is restricted and an unrestricted state in which movement is not restricted. The ratchet mechanism (19) comprises an operation part (27) that protrudes rearward from a main body (3) of the forceps device (1) and is operated so as to transition the states of the ratchet mechanism (19).

Classes IPC  ?

• A61B 17/29 - Pinces pour la chirurgie faiblement invasive

Abrégé

Disclosed are a means which enables simple and rapid detection of the presence or absence, and of the degree, of homologous recombination activity in an individual, and a means which is useful for detection and treatment of homologous recombination-restored cancer for which no treatment means is available at present. The nucleic acid construct of the present invention comprises: (1) a promoter region; (2) a mutant gene sequence containing a cleavage site in a gene sequence encoding a protein; and (3) a base sequence composed of a first homologous region and a second homologous region, the base sequence being capable of replacing, by homologous recombination, a partial region in the mutant gene sequence of (2), the partial region containing the cleavage site. The nucleic acid construct of the present invention can be used as a measurement reagent or kit for homologous recombination activity, a diagnostic agent for homologous recombination-deficient cancer, a therapeutic agent for homologous recombination-restored cancer, or the like.

Classes IPC  ?

• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/15 - Préparations médicinales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

A cell evaluation method includes acquiring a first evaluation index and a first index calculated using the first evaluation index with respect to comparative target cells in a culture process including a cell differentiation-inducing process in which cell differentiation is induced, calculating a second index on the basis of the first evaluation index with respect to evaluation target cells different from the comparative target cells, and evaluating differentiation of the evaluation target cells by comparing the first index with the second index.

Classes IPC  ?

• G06T 7/00 - Analyse d'image
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies

Abrégé

Disclosed is means which enables simple and rapid detection of the presence or absence of mismatch repair activity, and which is useful for diagnosis and treatment of mismatch repair-deficient cancers. In an integrated-type nucleic acid construct provided by the present invention, [promoter region], [5′-side region+first homologous region], and [second homologous region+3′-side region] are placed in the same nucleic acid molecule. In a divided-type nucleic acid construct, [promoter region], [5′-side region+first homologous region], and [second homologous region+3′-side region] are placed in two different nucleic acid molecules. The nucleic acid construct of the present invention can be used as a therapeutic agent for mismatch repair-deficient cancer, as a diagnostic agent for mismatch repair-deficient cancer, or as a companion diagnostic agent for predicting an effect of an anticancer drug for mismatch repair-deficient cancer, containing the nucleic acid construct.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
• C07K 14/54 - Interleukines [IL]
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Abrégé

An object of the present invention is to provide a method for detecting malignant ovarian tumor as distinguished from benign ovarian tumor, and a reagent that can be used for the method. Provided are a method for detecting malignant ovarian tumor (excluding high-grade serous carcinoma) as distinguished from benign ovarian tumor, characterized by measuring the amount of TFPI2 in a sample from a patient, and a reagent for detecting malignant ovarian tumor (excluding high-grade serous carcinoma) as distinguished from benign ovarian tumor contains an antibody that specifically recognizes TFPI2 processing polypeptide and intact TFPI2.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Developed is a method for creating cartilage tissue to solve the following problems. 1. Cartilage differentiation is not hindered by forming. 2. The cartilage can be formed into an intended shape without using a scaffold.　A method for producing artificial cartilage tissue comprises: forming a spheroid containing cartilage precursor cells into a desired shape while seeding the spheroid onto a support; culturing the spheroid while supplying a culture medium from the front side and the rear side of the surface onto which the spheroid has been seeded, and fusing the spheroids with each other; and maturing the fused spheroid into cartilage tissue in vitro.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
• A61L 27/38 - Cellules animales

Abrégé

Disclosed are a means that enables simple, rapid detection of the existence and degree of HR activity in an individual and a means useful in the detection and treatment of homologous recombination repair cancers. The nucleic acid construct of the present invention includes a set of a first nucleic acid molecule and a second nucleic acid molecule. The first nucleic acid molecule includes a promoter region and, operably linked downstream thereof, a mutant gene sequence having a cleavage site in the interior of a gene sequence that encodes a protein, and the second nucleic acid molecule includes a complementary region constituting a first homologous region and a second homologous region capable of substituting by homologous recombination the partial region including the cleavage site in the mutant gene sequence. The construct is useful as a reagent or kit for measuring homologous recombination activity, as a diagnostic agent for homologous recombination deletion cancers, as a therapeutic agent for homologous recombination repair cancers, etc.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
• G01N 33/15 - Préparations médicinales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The disclosure provides a method for producing hepatocytes or hepatic progenitor cells; a method for suppressing hepatocyte aging using a drug causing histone hyperacetylation; a hepatocyte anti-aging agent; a method for increasing hepatocyte plasticity; and a drug for increasing hepatocyte plasticity.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

A cancer treatment apparatus including a magnetic field generator that generates a magnetic field of 100 kHz to 300 kHz to be applied to affected tissues.

Classes IPC  ?

• A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants

Abrégé

The present invention relates to a method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis. The first nucleic acid comprises a first common sequence tract, a variable sequence tract and a second common sequence tract and the second nucleic acid comprises a first common sequence tract, optionally an variable sequence tract and a second common sequence tract. The first and the second nucleic acid sequence is contacted with a probe sequence that is reverse complementary to the first and second common sequence tract under conditions allowing the hybridization of the probe sequence to the first and second nucleic acid sequence, thereby forming a first probe hybrid and a second probe hybrid. Subsequently, the first and second probe hybrids are submitted to electrophoresis to detect the electrophoretic mobility of the first and second probe hybrid.

Classes IPC  ?

• C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
• G01N 27/447 - Systèmes utilisant l'électrophorèse

Abrégé

A method for screening for a therapeutic drug for a disease involving excessive activation of a complement, using a s cytotoxicity marker associated with the complement as an index, including (1a) a step of adding a complement to a cell produced from a stem cell to cause the cell to form a cytotoxicity marker associated with the complement, and (2a) a step of adding a therapeutic drug candidate, and selecting a substance that decreases the amount of the cytotoxicity marker is provided by the present invention.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The purpose of the present invention is to provide: a biomarker by which embryos having a high implantation/pregnancy probability, i.e., having high fertility can be selected from among embryos obtained by in vitro fertilization and then embryo culturing in infertility treatment; and a determination criterion thereof. The present invention provides a criterion with which an egg suitable for implantation/pregnancy can be determined, by measuring the concentration of soluble CD163 present in a follicular fluid to be collected simultaneously with the egg at the time of egg collection in infertility treatment or in a serum immediately before the egg collection.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/12 - Gènes codant pour des protéines animales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The purpose of the present invention is to provide: a biomarker by which embryos having a high implantation/pregnancy probability, i.e., having high fertility can be selected from among embryos obtained by in vitro fertilization and then embryo culturing in infertility treatment; and a determination criterion thereof. The present invention provides a criterion with which an egg suitable for implantation/pregnancy can be determined, by measuring the concentration of soluble CD163 present in a follicular fluid to be collected simultaneously with the egg at the time of egg collection in infertility treatment or in a serum immediately before the egg collection.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/12 - Gènes codant pour des protéines animales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire

Abrégé

Provided are: a method for producing a non-human model animal with a mental disorder or neurological disorder that is attributed to an increase or decrease in the expression of an AMPA receptor gene or an increase or decrease in the expression or function of an AMPA receptor in a predetermined region in the brain; a non-human model animal with the mental disorder or neurological disorder; and a screening method for discovering a prophylactic or therapeutic agent for the mental disorder or neurological disorder, using the non-human model animal.　This method is for producing a non-human model animal with a mental disorder or neurological disorder that is attributed to an increase or decrease in the expression of an AMPA receptor gene or an increase or decrease in the expression or function of an AMPA receptor in a predetermined region in the brain. The method comprises: a step for decreasing or increasing at least one selected from the group consisting of the expression of the AMPA receptor gene or the AMPA receptor, and the function of the AMPA receptor, in the predetermined region of the non-human animal, compared to a wild type, or a step for inhibiting or activating a nervous pathway connecting the predetermined region with another region.

Classes IPC  ?

• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61P 25/24 - Antidépresseurs
• C12N 15/09 - Technologie d'ADN recombinant
• C12N 15/12 - Gènes codant pour des protéines animales

Abrégé

The present invention provides means for producing an organoid close to an organ in a living body and capable of secretion of a plasma protein and immune response. A matrix composition of the present invention provided as such means includes: (1) a first matrix containing one or more cells selected from the group consisting of vascular cells, nerve cells, and blood cells; and (2) a second matrix containing to cells constituting an organ and/or an organoid, in which the first matrix envelops the second matrix, and the first matrix has at least one opening.

Classes IPC  ?

• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus

Abrégé

Provided is a coating-fixing agent for transplanting a cell or a tissue onto the surface of an organ, intestinal membrane, peritoneal membrane, etc. Provided are: a formulation for coating and fixing a graft, the formulation comprising alginate; a formulation kit for coating and fixing a graft, comprising a formulation containing alginate and a divalent or higher valent metal salt in combination; and a method for transplanting a graft, comprising: transplanting the graft to a transplant site of a human or a non-human animal, and coating the graft with alginate.

Classes IPC  ?

• A61L 24/08 - Polysaccharides
• C09D 105/04 - Acide alginiqueSes dérivés

Abrégé

The present invention provides a method of constituting a tissue construct in vitro using a tissue without depending on scaffold materials. A method of integrating a biological tissue with a vascular system in vitro, comprising coculturing a biological tissue with vascular cells and mesenchymal cells. A biological tissue which has been integrated with a vascular system by the above-described method. A method of preparing a tissue or an organ, comprising transplanting the biological tissue described above into a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed. A method of regeneration or function recovery of a tissue or an organ, comprising transplanting the biological tissue described above into a human or a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed. A method of preparing a non-human chimeric animal, comprising transplanting the biological tissue described above into a non-human animal and differentiating the biological tissue into a tissue or organ in which vascular networks have been constructed. A method of evaluating a drug, comprising using at least one member selected from the group consisting of the biological tissue described above, the tissue or organ prepared by the method described above, and the non-human chimeric animal prepared by the method described above. A composition for regenerative medicine, comprising a biological tissue which has been integrated with a vascular system by the method described above.

Classes IPC  ?

• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C07D 499/21 - Composés hétérocycliques contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. des composés contenant un système cyclique de formule p. ex. pénicillines, pénèmesCes systèmes cycliques étant ultérieurement condensés, p. ex. condensés en position 2,3 avec des hétérocycles contenant de l'oxygène, de l'azote ou du soufre avec un atome d'azote lié directement en position 6 et un atome de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. un radical ester ou nitrile, lié directement en position 2
• A61L 27/38 - Cellules animales
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61K 35/44 - VaisseauxCellules de muscles vasculaires lissesCellules endothélialesCellules progénitrices endothéliales
• A61K 49/00 - Préparations pour examen in vivo

Abrégé

The present invention addresses the problem of providing a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method that enable the detection of SARS-CoV-2 in a simple manner and with higher sensitivity. The present invention provides a SARS-CoV-2 detection kit for specifically detecting a nucleocapsid protein (NP) contained in a biological sample, the SARS-CoV-2 detection kit comprising at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), wherein the antibody includes at least one antibody of which the subclass is IgG2b, and the kit includes a first container that receives a silver-containing compound, and a second container that receives a reducing agent that can reduce silver ions.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention provides a means for suppressing formation and/or proliferation of undesired cells derived from stem cells in a cell population containing cells differentiated from stem cells. The nutrition composition according to the present invention is a nutrition composition for suppressing formation and/or proliferation of undesired cells derived from stem cells in a cell population containing cells differentiated from stem cells, the nutrition composition containing at least one essential amino acid selected from the group consisting of isoleucine, leucine, methionine, lysine, phenylalanine, tryptophan, threonine and histidine except valine, and optionally containing a non-essential amino acid(s).

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/4172 - Acides imidazole-alkanecarboxyliques, p. ex. histidine
• A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
• A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
• A23L 33/175 - Acides aminés

Abrégé

A game device (10) is provided with: an input unit (11A) that receives input of a physical amount which reflects at least one of a respiratory function, a deglutition function, and a vocalization function by a user who plays a game and which has a parameter with a state thereof made variable; and an adjustment unit (11B) for adjusting the parameter to be more advantageous in the development of the game as the degree in which, the state of the physical amount inputted by the input unit (11A) becomes effective as training for at least one of the respiratory function, the deglutition function, and the vocalization function of the user, become higher.

Classes IPC  ?

• A63F 13/215 - Dispositions d'entrée pour les dispositifs de jeu vidéo caractérisées par leurs capteurs, leurs finalités ou leurs types comprenant des moyens de détection des signaux acoustiques, p. ex. utilisant un microphone
• A63F 13/46 - Calcul du score du jeu
• A63F 13/53 - Commande des signaux de sortie en fonction de la progression du jeu incluant des informations visuelles supplémentaires fournies à la scène de jeu, p. ex. en surimpression pour simuler un affichage tête haute [HUD] ou pour afficher une visée laser dans un jeu de tir
• A63F 13/69 - Création ou modification du contenu du jeu avant ou pendant l’exécution du programme de jeu, p. ex. au moyen d’outils spécialement adaptés au développement du jeu ou d’un éditeur de niveau intégré au jeu en permettant l'utilisation ou la mise à jour d'éléments spécifiques du jeu, p. ex. déblocage d’options, d’éléments, de niveaux ou de versions cachés

Abrégé

Provided is a schizophrenia biomarker. A schizophrenia examination method including measuring the expression level of non-phosphorylated collapsin response mediator protein 2 (CRMP2) and/or phosphorylated CRMP2 in a sample derived from a subject.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention provides a composition suitable as a composition for treating blood coagulation and/or complement disorders (raw materials for producing therapeutic agents for these diseases) and a method for effectively producing the composition. A method for producing a composition for treating blood coagulation and/or complement disorders according to the present invention includes the following steps of: (1) embedding an organoid formed from vascular endothelial cells or vascular endothelial cells and hepatocytes, in an extracellular matrix; (2) culturing the extracellular matrix; and (3) collecting a culture supernatant from the culture obtained in the step (2).

Classes IPC  ?

• A61K 35/44 - VaisseauxCellules de muscles vasculaires lissesCellules endothélialesCellules progénitrices endothéliales
• A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques

Abrégé

Provided is a means for rapidly analyzing whether an interstitial pneumonia patient, who exhibits a respiratory distress symptom and is suspected to suffer from an acute exacerbation, suffers from an acute exacerbation or suffers from an acute respiratory exacerbation caused by a pathosis that is not an acute exacerbation. Provided is a method comprising: a step for obtaining the measured value of the concentration of heme oxygenase-1 in a blood specimen collected from an interstitial pneumonia patient exhibiting a respiratory distress symptom; and a step for determining, on the basis of the measured value, whether the symptom of the patient is caused by an acute exacerbation or caused by a pathosis that is not an acute exacerbation. Moreover, provided are: a kit for performing said method; and a patient sorting method and a treatment policy determination method which are based on said method.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une oxydoréductase
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The purpose of the present invention is to provide a food composition, a pharmaceutical composition, a quasi drug composition, a cosmetic composition and a sundry article, each being for preventing or treating COVID-19. A food composition, a pharmaceutical composition, a quasi drug composition, a cosmetic composition and a sundry article, each being for preventing or treating COVID-19 and comprising at least one member selected from among a cat's claw extract, a ginger extract, pteropodine and a pharmaceutically acceptable salt thereof, isopteropodine and a pharmaceutically acceptable salt thereof, 6-gingerol and a pharmaceutically acceptable ether thereof and 6-shogaol and a pharmaceutically acceptable ether thereof.

Classes IPC  ?

• A61K 36/74 - Rubiaceae (famille de la garance)
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 8/35 - Cétones, p. ex. quinones, benzophénone
• A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61K 8/9794 - Liliopsida [monocotylédones]
• A61K 31/12 - Cétones
• A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
• A61K 36/9068 - Zingiber, p. ex. gingembre
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61Q 1/00 - Préparations pour le maquillagePoudres corporellesPréparations pour le démaquillage
• A61Q 5/02 - Préparations pour le lavage des cheveux
• A61Q 5/06 - Préparations pour mettre les cheveux en forme, p. ex. pour mettre en forme ou colorer temporairement
• A61Q 19/00 - Préparations pour les soins de la peau

Abrégé

The present invention provides a prophylactic and/or therapeutic agent for diseases accompanied by fibrosis. A pharmaceutical composition for preventing and/or treating a disease accompanied by fibrosis in an organ and/or a tissue, which comprises a cell mixture and/or a cell condensate comprising mesenchymal cells and vascular cells (and hepatocytes, optionally). An agent capable of inhibiting organ and/or tissue fibrosis, which comprises both mesenchymal cells and vascular cells or a cell condensate thereof. By transplanting into a subject a cell mixture and/or a cell condensate comprising mesenchymal cells and vascular cells (and optionally, hepatocytes), expression levels of fibrolysis enzymes (fibrolytic factors) such as MMP1 or MMP13 are elevated, which eventually enables inhibition of fibrosis in an organ and/or a tissue, as well as prevention and/or treatment of a disease accompanied by fibrosis in an organ and/or a tissue.

Classes IPC  ?

• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61K 35/44 - VaisseauxCellules de muscles vasculaires lissesCellules endothélialesCellules progénitrices endothéliales
• A61K 35/407 - FoieHépatocytes
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/06 - Tripeptides
• A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

A bilirubin concentration measurement system including: a sensor device attachable to a subject; and a terminal device capable of wirelessly communicating with the sensor device. The sensor device includes: a light emitting diode that emits blue light; a light emitting diode that emits green light; a light detection diode that detects reflected light that is the blue light having been incident on skin of the subject and reflected, and detects reflected light that is the green light having been incident on the skin of the subject and reflected; and a communication unit that wirelessly transmits information about intensities of the reflected light detected by the photodiode. The terminal device includes: a communication unit that receives the information about the intensities of the reflected light transmitted from the sensor device; and a computing unit that calculates a bilirubin concentration using the information about the intensities of the reflected light.

Classes IPC  ?

• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale

Abrégé

The present invention addresses the problem of providing a means for detecting a constituting protein of nucleocapsid derived from SARS-CoV-2. This problem has been solved by providing an antibody binding to a constituting protein of nucleocapsid derived from SARS-CoV-2 or a fragment of the antibody, a method for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid with the use of the antibody or a fragment thereof, a kit for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid, said kit containing the antibody or a fragment thereof, etc.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The present invention addresses the problem of providing a method for detecting pancreatic cancers and a reagent usable in the method. The method for detecting pancreatic cancers is characterized by measuring the amount of TFPI2 in body fluid sampled from a subject. Furthermore, an antibody that specifically recognizes TFPI2 processing polypeptide and intact TFPI2 is included in the reagent for detecting pancreatic cancers.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12N 15/12 - Gènes codant pour des protéines animales
• G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique

Abrégé

The present invention addresses the problem of providing a means for accurately, easily and quickly detecting an anti-SARS-CoV-2-antibody. A solution to this problem is achieved by providing a SARS-CoV-2-derived nucleocapsid fragment, a method and a kit for detecting an anti-SARS-CoV-2-antibody from human-derived blood, plasma and/or serum with the use of the fragment, etc.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 33/535 - Production de composés immunochimiques marqués avec un marqueur enzymatique
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The purpose of the present invention is to provide a mouse model for pancreatic cancer similar to human pancreatic cancer. Specifically, the present invention pertains to a human pancreatic cancer mouse model which carries a pancreatic cancer organoid containing a human pancreatic cancer cell line S2-130.

Classes IPC  ?

• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 35/00 - Agents anticancéreux
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• C12N 5/09 - Cellules tumorales
• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang

Abrégé

The present invention addresses the problem of providing a method for detecting malignant ovarian tumors distinctly from benign ovarian tumors and a reagent that can be used in the method. This method for detecting malignant ovarian tumors (excluding high-grade serous carcinoma) distinctly from benign ovarian tumors is characterized in that the amount of TFPI2 in a sample originating from a patient is measured. In addition, an antibody that specifically recognizes TFPI2 processing polypeptide and intact TPFI2 is included in a reagent for detecting malignant ovarian tumors (excluding high-grade serous carcinoma) distinctly from benign ovarian tumors.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention addresses the problem of providing a method for detecting malignant ovarian tumors distinctly from benign ovarian tumors and a reagent that can be used in the method. This method for detecting malignant ovarian tumors (excluding high-grade serous carcinoma) distinctly from benign ovarian tumors is characterized in that the amount of TFPI2 in a sample originating from a patient is measured. In addition, an antibody that specifically recognizes TFPI2 processing polypeptide and intact TPFI2 is included in a reagent for detecting malignant ovarian tumors (excluding high-grade serous carcinoma) distinctly from benign ovarian tumors.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention provides a marker gene capable of detecting the undifferentiated cells that remain or become included in a differentiated cell population. Undifferentiated cells present in a differentiated cell population are detected by using at least one gene selected from the group consisting of ESRG, VSNL1, THY1, SFRP2, SPP1, USP44 and CNMD as an undifferentiation marker. A method of detecting undifferentiated cells; a method of using the gene as an undifferentiation marker; and a kit for detecting undifferentiated cells. A method of selecting an undifferentiated cell clone is also provided.

Classes IPC  ?

• C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
• C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Disclosed are a means that enables the rapid and convenient detection of the presence/absence and extent of homologous recombination activity in an individual, and a means that is not a current treatment means and is useful for the detection and treatment of homologous recombination repair cancers. A nucleic acid construct according to the present invention comprises (1) a promoter region, (2) a mutant gene sequence that has a cleavage site in the interior of a protein-encoding gene sequence, and (3) a base sequence that is a partial region in the mutant gene sequence of (2), is capable of replacing, by homologous recombination, a partial region that contains the cleavage site, and is constituted of a first homologous region and a second homologous region. This nucleic acid construct can be used, for example, as a reagent or kit for measuring homologous recombination activity, as a diagnostic agent for homologous recombination deletion cancers, and as a therapeutic agent for homologous recombination repair cancers.

Classes IPC  ?

• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux
• C12N 15/31 - Gènes codant pour des protéines microbiennes, p. ex. entérotoxines
• C12N 15/869 - Vecteurs herpèsviraux
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
• G01N 33/15 - Préparations médicinales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Disclosed is a means that enables simple and quick detection of the presence or absence of a mismatch repair activity and that is useful in diagnosing or treating mismatch repair deficient cancers. In an integrated type nucleic acid construct provided by the present invention, [promoter region], [5' terminal region + first homologous region] and [second homologous region + 3' terminal region] are disposed on a single nucleic acid molecule. In a split type nucleic acid construct, [promoter region] and [5' terminal region + first homologous region] are disposed on a nucleic acid molecule and [second homologous region + 3' terminal region] are disposed on another nucleic acid molecule that is different from the former nucleic acid molecule. The nucleic acid construct of the present invention can be used as a therapeutic agent for mismatch repair deficient cancers, a diagnostic agent for mismatch repair deficient cancers, a companion diagnostic agent for predicting the effect of an anticancer agent on mismatch repair deficient cancers, etc., each agent comprising the nucleic acid construct.

Classes IPC  ?

• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance
• C07K 14/525 - Facteur de nécrose de tumeurs [TNF]
• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance

Abrégé

Provided is a maturation prediction system improved in terms of ease of use, versatility, and prediction accuracy.　This maturation prediction system for plants is characterized in that the system generates a first model for which weather information is input and a predicted intermediate state of a plant of interest is output and a second model for which information about the intermediate state is input and a prediction of maturation of the plant of interest is output, and in that weather information for a predicted maturation time is input to the first model and the predicted intermediate state of the plant of interest at the predicted maturation time output from the first model is input to the second model, thereby outputting a prediction of maturation of the plant of interest at the predicted maturation time.

Classes IPC  ?

• A01G 7/00 - Botanique en général
• G06Q 50/02 - AgriculturePêcheForesterieExploitation minière

Abrégé

The present invention addresses the problem of providing a biomarker that makes it possible to diagnose colon cancer.　The present invention relates to a biomarker that is for assisting in the diagnosis of colon cancer and that contains a sugar chain selected from among the following substances (1)-(4): (1) at least one sugar chain that is present in alpha 1-antitrypsin and represented by formula 1 or 2; (2) a sugar chain that is present in leucine-rich alpha-2 glycoprotein and represented by formula 1; (3) at least one sugar chain that is present in alpha 1-antichymotrypsin and represented by formula 1 or 2; and (4) a sugar chain that is present in complement component 9 and represented by formula 1.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/81 - Inhibiteurs de protéase
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/15 - Inhibiteurs de protéases, p. ex. antithrombine, antitrypsine, hirudine
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Faecalibacterium bacterium or a processed product thereof.

Classes IPC  ?

• A61K 35/741 - Probiotiques
• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
• A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques

Abrégé

Provided is a marker gene capable of detecting the persistence/admixture of undifferentiated cells in a differentiated cell population. Undifferentiated cells present in a differentiated cell population are detected by using at least one gene selected from the group consisting of LINC00678 and PRDM14 as an undifferentiation marker. Also provided are a method for detecting undifferentiated cells, a method of use as an undifferentiation marker, and an undifferentiated cell detection kit, and a method for selecting an undifferentiated cell line.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C12N 5/0735 - Cellules souches embryonnairesCellules germinales embryonnaires
• C12N 5/09 - Cellules tumorales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12Q 1/6837 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide utilisant des réseaux de sondes ou des puces à sondes
• C12Q 1/6841 - Hybridation in situ
• C12Q 1/6844 - Réactions d’amplification d’acides nucléiques
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6862 - Réaction en chaine par ligase [LCR]
• C12Q 1/6869 - Méthodes de séquençage
• C12Q 1/6872 - Méthodes de séquençage faisant intervenir la spectrométrie de masse
• C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes

Abrégé

Provided is a sensitive and simple detection method, and a kit therefor, which detects undifferentiated human pluripotent stem cells which are mixed into an intermediate product of a regenerative medicine product and/or a final product thereof by using a nucleic acid isothermal amplification method, and specifically, the LAMP method. A method for detecting whether or not undifferentiated cells are present in a non-undifferentiated cell population, wherein RNA derived from an undifferentiated marker gene for which there is a significant difference in expression between an undifferentiated cell and a non-undifferentiated cell is detected using a nucleic acid isothermal amplification method in a specimen containing a nucleic acid derived from the cell population to be tested. A kit for testing whether or not undifferentiated cells are mixed in with a non-undifferentiated cell population, said kit containing a reagent capable of detecting RNA derived from an undifferentiated marker gene for which there is a significant difference in expression between an undifferentiated cell and a non-undifferentiated cell by using a nucleic acid isothermal amplification method.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• C12Q 1/6851 - Amplification quantitative
• C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]

Abrégé

This cell evaluation method comprises: in a culture stage involving the induction of cell differentiation during a process for inducing the cell differentiation, acquiring a first evaluation index relative to cells to be compared and a first index calculated with the use of the first evaluation index; calculating a second index relative to cells to be evaluated, said cells to be evaluated being different from the cells to be compared, on the basis of the first evaluation index; and then comparing the first index with the second index to thereby evaluate the differentiation of the cells to be evaluated.

Classes IPC  ?

• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
• G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné

Abrégé

The present invention provides a drug toxicity evaluation platform (evaluation method and kit therefor, etc.) that makes it possible to perform a detailed analysis of the likelihood that a drug will cause injury (DILI, etc.) to the liver or another organ. This method for evaluating drug toxicity includes a step for adding a drug to a co-culture of an organoid and blood cells, and a step for evaluating the toxicity of said drug to said organoid.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/078 - Cellules du sang ou du système immunitaire
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables

Abrégé

Provided are: a method for inducing hepatic progenitor cells which can overcome drawbacks in the prior art; and hepatic progenitor cells. Hepatocyte plasticity and senescence are controlled. A method for producing hepatocytes that includes dividing endodermal cells into hepatocytes in the presence of a member of the FGF family, HGF, and a member of IL6 family, and dexamethazone. Hepatocytes produced using the aforementioned method that can survive for 90 or more days while maintaining functionality as hepatocytes. A method for producing hepatic progenitor cells that includes culturing hepatocytes in the presence of a member of the FGF family. Alpha-fetoprotein (AFP)–negative hepatic progenitor cells produced using the aforementioned method that have proliferative ability and the ability to differentiate bidirectionally into hepatocytes and bile duct epithelial cells. A method for producing hepatocytes that includes inducing differentiation of the hepatic progenitor cells into hepatocytes. A method for producing bile duct cells that includes inducing differentiation of the hepatic progenitor cells into bile duct cells. A method for suppressing hepatocyte senescence using a drug which causes histone hyperacetylation. A hepatocyte senescence inhibitor that includes a drug that causes histone hyperacetylation as an active ingredient. A method for increasing hepatocyte plasticity using a drug that causes histone hyperacetylation. A drug that increases hepatocyte plasticity and includes a drug that causes histone hyperacetylation as an active ingredient. A method for producing a chimeric animal that includes transplanting into a non-human animal at least one cell selected from the group consisting of the hepatocytes, the hepatic progenitor cells, and the cells induced through differentiation from the hepatic progenitor cells. A composition for transplantation that includes at least one cell selected from the group consisting of the hepatocytes, the hepatic progenitor cells, and the cells induced by differentiation from the hepatic progenitor cells. A culture medium kit for inducing differentiation that includes: an agent containing FGF10, retinoic acid, and forskolin for use in a culture medium to be used to induce differentiation of the hepatic progenitor cells into bile duct cells; and a written explanation of the use of the agent in the culture medium to be used to induce differentiation. A medium containing FGF10, retinoic acid, and forskolin for inducing differentiation of the hepatic progenitor cells into bile duct cells. A liver regeneration promoter that includes a drug that causes histone hyperacetylation as an active ingredient.

Classes IPC  ?

• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/0735 - Cellules souches embryonnairesCellules germinales embryonnaires
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/09 - Technologie d'ADN recombinant
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61K 35/407 - FoieHépatocytes
• A61L 27/38 - Cellules animales
• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés

Abrégé

An object of the present invention is to provide a method for detecting renal cancer, and a reagent that can be used for the method. Provided is a method for detecting renal cancer, which includes measuring the amount of TFPI2 in a sample derived from a patient. An antibody that specifically recognizes NT-TFPI2 and intact TFPI2 is included in a detection reagent for renal cancer.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis. The first nucleic acid comprises a first common sequence tract, a variable sequence tract and a second common sequence tract and the second nucleic acid comprises a first common sequence tract, optionally an variable sequence tract and a second common sequence tract. The first and the second nucleic acid sequence is contacted with a probe sequence that is reverse complementary to the first and second common sequence tract under conditions allowing the hybridization of the probe sequence to the first and second nucleic acid sequence, thereby forming a first probe hybrid and a second probe hybrid. Subsequently, the first and second probe hybrids are submitted to electrophoresis to detect the electrophoretic mobility of the first and second probe hybrid.

Classes IPC  ?

• C12Q 1/6813 - Tests d’hybridation

Abrégé

The present invention provides a method of fusing cell masses. A method of fusing cell masses, comprising seeding cell masses on a plane capable of cell adhesion and culturing the cell masses as a culture medium is fed from both the obverse and reverse sides of the cell mass-seeded plane.

Classes IPC  ?

• C12N 5/16 - Cellules animales
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

Disclosed is a novel means for accurate qualitative and quantitative analyses for each N-glycosylation site. The method of analyzing N-linked sugar chain(s) of glycoprotein according to the present invention comprises: treating a part of a glycopeptide-containing sample to be analyzed with endo-β-N-acetylglucosaminidases to cleave off sugar chains while leaving one GlcNAc of the chitobiose core on the Asn at the N-glycosylation site; subjecting the obtained sugar chain-cleaved sample to preliminary liquid chromatography/mass spectrometry; predicting the retention time of the glycopeptide of interest and the mass-to-charge ratio (m/z) of the precursor ion in main analysis based on the results of the preliminary liquid chromatography/mass spectrometry; and carrying out the main analysis. By this method, the binding sites and structures of N-linked sugar chains in a glycoprotein can be analyzed. By using the sugar chain-cleaved sample as an internal standard in the main analysis, quantitative analysis of sugar chains at each glycosylation site also becomes possible.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C12Q 1/44 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase une estérase
• G01N 30/72 - Spectromètres de masse
• G01N 30/86 - Analyse des signaux
• H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
• G01N 30/02 - Chromatographie sur colonne

Abrégé

The present invention solves the following problems [1] to [3] found in conventional methods of preparing a three dimensional structure (organ primordium) by coculturing functional cells with umbilical cord-derived vascular endothelial cells and bone marrow-derived mesenchymal cells: [1] the quality of resultant organ primordia varies greatly depending on donors; [2] the growth capacities of cell sources are limited; and [3] it is difficult to secure immunocompatibility because cells are derived from different sources. An organ bud prepared from vascular cells, mesenchymal cells and tissue or organ cells, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells. A method of preparing an organ bud, comprising culturing vascular cells, mesenchymal cells and tissue or organ cells in vitro, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
• C12N 5/074 - Cellules souches adultes

Abrégé

A method for aggregating cell masses includes performing a cell mass aggregating step of rotating a rotating body containing a specific gravity adjustment solution and cell masses to aggregate the cell masses, the specific gravity adjustment solution having biocompatibility, the cell masses having a lower specific gravity than the specific gravity adjustment solution.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

Provided is an illness aggravation estimation system that estimates aggravation of an illness in a patient with high precision. The illness aggravation estimation system acquires sickbed image data in which images of an imaging area including the sickbed of a patient are captured chronologically, analyzes the movements of the patient or of a body part of the patient captured in the acquired sickbed image data, uses the analyzed movements as a basis to perform scoring of at least one of a consciousness state and oxygen administration which are items included in indices for an early warning score, and estimates aggravation of an illness in the patient.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

The present invention provides a method for screening a therapeutic agent of a disease, in which over-activation of a complement is engaged, by taking, as an indicator, a cytotoxic marker associated with the complement, wherein the method includes: (1a) a process for adding the complement to a cell manufactured from a stem cell, and forming the cytotoxic marker associated with the complement; and (2a) a process for adding a therapeutic agent candidate material to select a material which lowers the amount of the cytotoxic marker.

Classes IPC  ?

• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• C12Q 1/6851 - Amplification quantitative
• G01N 33/15 - Préparations médicinales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention provides a means for producing an organoid capable of secretion of plasma proteins, immune response, etc., in a manner close to that of an organ in a living body. As such a means, this matrix composition includes: (1) a first matrix that includes one or more cells selected from the group comprising vascular cells, nerve cells, and blood cells; (2) a second matrix that includes cells constituting an organ, and/or an organoid, and here, the first matrix encapsulates the second matrix, and the first matrix has at least one opening.

Classes IPC  ?

• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

Provided is a coating-securing agent for transplanting cells or a tissue onto the surface of an organ, a mesentery, a peritoneum, etc. Provided are: a formulation which is for coating-securing an implant, and contains alginate; a formulation kit for coating-securing an implant, in which an alginate-containing formulation and a di- or higher-polyvalent metallic salt are combined; and a method for transplanting an implant, the method comprising a step for transplanting an implant onto a transplantation site of a human or a non-human animal and coating the implant with alginate.

Classes IPC  ?

• A61L 31/02 - Matériaux inorganiques
• A61L 31/04 - Matériaux macromoléculaires
• A61L 31/12 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
• A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61L 31/16 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• C12N 11/04 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique piégées à l’intérieur du support, p. ex. dans un gel ou dans des fibres creuses
• C12N 11/10 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique le support étant un hydrate de carbone
• A61L 27/20 - Polysaccharides

Abrégé

An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/06 - Tripeptides
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

The present invention provides a composition suitable for treating blood coagulation and/or complement disorders (a raw material for producing a therapeutic agent for such disorders) and an effective production method therefor. This method for producing a composition for treating blood coagulation and/or complement disorders comprises the following steps: (1) a step in which an organoid prepared from vascular endothelial cells or from vascular endothelial cells and liver cells is embedded in an extracellular matrix; (2) a step in which the extracellular matrix is cultivated; and (3) a step in which a culture supernatant is recovered from the culture cultivated in step (2).

Classes IPC  ?

• A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
• A61P 37/02 - Immunomodulateurs
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/36 - Facteurs de coagulation sanguine ou de fibrinolyse
• A61K 38/37 - Facteurs VIII
• A61K 35/407 - FoieHépatocytes
• A61K 35/44 - VaisseauxCellules de muscles vasculaires lissesCellules endothélialesCellules progénitrices endothéliales

Abrégé

The present invention provides a system for artificially inducing and regulating “tissue interactions” among multiple tissues. A construct for transplantation into a living body, which comprises a structure and a cell mass linked to each other, the structure being an object having a three-dimensional structure and capable of mimicking or resembling a structure and/or a function of the living body.

Classes IPC  ?

• A61L 27/38 - Cellules animales
• A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61L 27/40 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés

Abrégé

Provided is a method for predicting, in the stage of undifferentiated cells, the possibility of contamination with undifferentiated cells after the differentiation of the cells. The differentiation resistance of undifferentiated cells is evaluated by measuring (i) and/or (ii). (i) Expression level and/or promoter activity of at least one gene selected from the group consisting of ZNF354C, C12orf56, ZNF578, DPP6 and MIR886. (ii) Methylation state of the promoter of at least one gene selected from the group consisting of ZNF354C, C12orf56, ZNF578, DPP6 and MIR886.

Classes IPC  ?

• C12N 5/0735 - Cellules souches embryonnairesCellules germinales embryonnaires
• C12N 5/095 - Cellules souchesCellules progénitrices
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/09 - Technologie d'ADN recombinant
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12Q 1/6813 - Tests d’hybridation
• C12Q 1/6837 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide utilisant des réseaux de sondes ou des puces à sondes
• C12Q 1/6841 - Hybridation in situ
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6869 - Méthodes de séquençage
• C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
• C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Provided is a prophylactic and/or therapeutic agent for diseases accompanied by fibrosis. The present invention provides: a medicinal composition for preventing and/or treating diseases accompanied by organ and/or tissue fibrosis, the composition comprising a cell mixture and/or a cell aggregate that includes mesenchymal cells and endothelial cells (hepatocytes may be further included); and an inhibitor for inhibiting organ and/or tissue fibrosis, the inhibitor comprising both mesenchymal cells and endothelial cells or a cell aggregate thereof. A cell mixture and/or a cell aggregate that includes mesenchymal cells and endothelial cells (hepatocytes may be further included) is transplanted to a subject, so that an expression of fibrinolysins such as MMP1 and MMP13 (fibrinolytic system factors) increases and can inhibit organ and/or tissue fibrosis, thereby preventing and/or treating diseases accompanied by organ and/or tissue fibrosis.

Classes IPC  ?

• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61K 35/407 - FoieHépatocytes
• A61K 35/44 - VaisseauxCellules de muscles vasculaires lissesCellules endothélialesCellules progénitrices endothéliales
• A61K 35/545 - Cellules souches embryonnairesCellules souches pluripotentesCellules souches pluripotentes induitesCellules souches non caractérisées
• A61L 27/38 - Cellules animales

Abrégé

A bilirubin concentration measurement system (1) according to the present invention is provided with a sensor device (10) attachable to a test body, and a terminal device (20) capable of wirelessly communicating with the sensor device (10). The sensor device (10) is provided with: a light emitting element (12) which emits blue light; a light emitting element (13) which emits green light; an optical detection element (14) which detects reflected light due to the blue light incident on, and reflected by, a skin of the test body, and reflected light due to the green light incident on, and reflected by, the skin of the test body; and a communication unit (16) which wirelessly transmits information pertaining to the intensity of the reflected light detected by the optical detection element (14). The terminal device (20) is provided with a communication unit (21) which receives the information pertaining to the intensity of the reflected light transmitted from the sensor device (10), and a computing unit (22) which calculates a bilirubin concentration using the information pertaining to the intensity of the reflected light.

Classes IPC  ?

• G01N 21/27 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale

Abrégé

The present invention provides a means for inhibiting formation and/or growth of non-objective cells derived from stem cells in a cell population including cells differentiated from the stem cells. A nutrition composition according to the present invention contains one or more essential amino acids selected from the group consisting of isoleucine, leucine, methionine, lysine, phenylalanine, tryptophan, threonine, and histidine, but excluding valine, optionally contains a nonessential amino acid, and inhibits formation and/or growth of non-objective cells derived from stem cells in a cell population including cells differentiated from the stem cells.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A23L 33/175 - Acides aminés
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
• A61K 31/4172 - Acides imidazole-alkanecarboxyliques, p. ex. histidine
• A61P 3/02 - Nutriments, p. ex. vitamines, minéraux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C12N 5/0735 - Cellules souches embryonnairesCellules germinales embryonnaires
• C12N 5/074 - Cellules souches adultes

Abrégé

Provided is a reproductive medicine support system which supports persons who are involved and work in reproductive medicine. Image analysis processing performed by an analysis means includes: determination processing for determining sperm imaged in video data; and analysis processing for analyzing the sperm determined in the determination processing. On a working screen, displayed are first additional displays (displays G11–G13) based on the analysis processing pertaining to sperm displayed in a display region on a main screen G1 among the sperm determined by the determination processing; and second additional displays (displays G22-G25) based on the analysis processing pertaining to all the sperm determined by the determination processing or sperm displayed in a display region of a sub-screen G2 among the sperm determined by the determination processing.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux

Abrégé

The present invention addresses the problem of providing a pancreatic cancer determination marker having a high accuracy (correctness and precision). The present invention pertains to a pancreatic cancer determination marker, a pancreatic cancer determination method, a method for acquiring data for determining a pancreatic cancer, a pancreatic cancer determination kit, and the like.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/66 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les sucres du sang, p. ex. le galactose

Abrégé

Provided is a marker gene capable of detecting the persistence/admixture of undifferentiated cells in a differentiated cell population. Undifferentiated cells present in a differentiated cell population are detected by using at least one gene selected from the group consisting of ESRG, VSNL1, THY1, SFRP2, SPP1, USP44, and CNMD as an undifferentiation marker. A method for detecting undifferentiated cells, a method of use as an undifferentiation marker, and an undifferentiated cell detection kit. Also provided is a method for selecting an undifferentiated cell line.

Classes IPC  ?

• C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
• C12Q 1/6834 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide
• C12Q 1/6837 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide utilisant des réseaux de sondes ou des puces à sondes
• C12Q 1/6841 - Hybridation in situ
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6869 - Méthodes de séquençage
• C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
• C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

A power supply apparatus includes a power supply configured to apply an alternating current to a magnetic field generation apparatus; and a controller configured to control the alternating current applied by the power supply. The controller controls the power supply to apply the alternating current having a waveform pattern including a plurality of current waveforms having different frequency spectrums from each other.

Classes IPC  ?

• A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
• A61N 1/40 - Application de champs électriques par couplage inductif ou capacitif
• H05B 6/06 - Commande, p. ex. de la température, de la puissance
• H05B 6/04 - Sources de courant
• G03G 15/20 - Appareils pour procédés électrographiques utilisant un dessin de charge pour le fixage, p. ex. par la chaleur

Abrégé

A cancer treatment apparatus including a magnetic field generator that generates a magnetic field of 100 kHz to 300 kHz to be applied to affected tissues.

Classes IPC  ?

• A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants

Abrégé

The purpose of the invention is to provide a method for identifying molecules involved in refractory cancers. Furthermore, the purpose of the invention is to provide a method for identifying drugs effective against refractory cancers. Additionally, the purpose of the invention is to provide a drug effective against recurrent cancers. Provided is a method for screening for molecules involved in refractory cancers, wherein the expression level of an EMT-associated molecule at pre- and post-administration of an anticancer agent is measured in stromal cells and/or cancer cells in tissue that reconstructs the cancer microenvironment, and an EMT-associated molecule presenting a higher expression level at post-administration of the anticancer agent than at pre-administration is scored as being involved in refractory cancers. Also provided is a method for screening for drugs effective against refractory cancers, wherein the expression level of an EMT-associated molecule at pre- and post-administration of an anticancer agent is measured in stromal cells and/or cancer cells in tissue that reconstructs the cancer microenvironment, and an EMT-associated molecule presenting a higher expression level at post-administration of the anticancer agent than at pre-administration is scored as being involved in refractory cancers, while a substance that can inhibit the function of this EMT-associated molecule is scored as a drug effective against refractory cancers. Further provided is a drug for treating and/or preventing tumor recurrence as a combination of an anticancer agent with an inhibitor targeted to the NOTCH3 signal.

Classes IPC  ?

• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12Q 1/6837 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide utilisant des réseaux de sondes ou des puces à sondes
• C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
• G01N 33/15 - Préparations médicinales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Provided is a technique for accurately evaluating the prognosis of a cancer. This method comprises: measuring the expression level of an EMT-related molecule in cancer cells and stromal cells in a cancer tissue from a patient or a tissue reconstructing the cancer microenvironment including cancer cells from the patient; and predicting the prognosis of the patient on the basis of this level.

Classes IPC  ?

• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• C12Q 1/6813 - Tests d’hybridation
• C12Q 1/6851 - Amplification quantitative
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6869 - Méthodes de séquençage
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
• A61P 35/00 - Agents anticancéreux
• C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle

Abrégé

Provided is a method for fusing cell masses. The cell mass fusion method comprises: disseminating cell masses on a surface to which cells can adhere; and culturing the cell masses while supplying a culture medium from the front side and the rear side of the surface on which the cell masses have been disseminated.

Classes IPC  ?

• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires